Date: 2013-04-30
Type of information: Pipeline acquisition
Compound: 15 biologic development programs
Company: Ligand Pharmaceuticals (USA) Selexis (Switzerland)
Therapeutic area: Cancer - Oncology - Inflammatory diseases - Autoimmune diseases
Type agreement: acquisition
Action mechanism:
Disease:
Details: Ligand Pharmaceuticals has acquired a portfolio of potential future milestone and royalty payments for more than 15 biologic development programs from Selexis. Each acquired program is fully funded by a development partner. Geneva, Switzerland -based Selexis is a privately held global life science company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs.
The basis for the development programs is Selexis’ proprietary technology platform for generating stable and high performing manufacturing mammalian cell lines for biologic therapeutics. The acquired assets include potentially groundbreaking mechanisms of action of biological drugs and expand Ligand’s presence in large, growing therapeutic markets such as oncology, inflammation and autoimmune diseases. The acquired programs are in various stages of preclinical and clinical development.
Financial terms:
Latest news:
